Orthofix Medical, Inc. reported $203.121 million in sales and ($16,003) million in operating losses for the quarter ending June 30, 2025. The second quarter beat expectations for both revenue and EPS.
| Orthofix Medical, Inc. 2025 Report ($000s): 3 Months Ended 06/30/25 | ||||||
| 3 Month Sales | 6 Month Sales | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $198,620 | $203,121 | 2.27% | $387,228 | $396,767 | 2.46% | |
| Op Profit | Op Profit | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| -$24,906 | -$16,003 | 35.75% | -$54,243 | -$64,876 | -19.60% | |
| -12.54% | -7.88% | -14.01% | -16.35% | |||
| EPS | EPS | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| -$0.88 | -$0.36 | 59.09% | -$1.8400 | -$1.7100 | 7.07% | |
| 2025 Sales Estimate | 2026 Sales Estimate | |||||
| Consensus | Change | Consensus | Change | |||
| $825,980 | 4.24% | $880,130 | 6.66% | |||
Source: RRY Publications LLC
Massimo’s 3-Year Plan Is Delivering
In an era when “strategic transformation” often translates into cost cuts and a PowerPoint deck, Orthofix’s 2025 mid-year report is evidence that this team is delivering real-world growth.
On the company’s Q2 earnings call, President & CEO Massimo Calafiore and CFO Julie Andrews reported $200.7 million in pro forma net sales, up 4% year-over-year in constant currency. The momentum, Calafiore insists, comes from sticking to the three-year plan he rolled out to analysts last year—one built on tightening commercial focus, ramping product innovation, and pushing deeper into underpenetrated U.S. spine markets.
Spine is feeling the lift. The U.S. Anterior Lumbar and Cervical Fusion portfolios grew more than 15%, powered by the launch of the Reef L Lateral Lumbar Interbody System and FDA clearance for the VIRATA Spinal Fixation System—already in limited release with surgeon adoption topping 80%.
Specialized orthopedics is surging. The TrueLok Elevate Transverse Bone Transport System—designed to improve circulation and healing in diabetic foot wounds while reducing amputation risk—has already been used in over 200 procedures this year. This strengthens Orthofix’s bid to dominate the limb reconstruction space and tap into the fast-growing diabetic wound care market.
Bone Growth Therapy (BGT) stays on offense. With the AccelStim 2.0 FDA-approved and slated for a second-half launch, Calafiore called BGT’s performance “a testament to commercial excellence” and a powerful cross-selling engine between spine and ortho.
Tariff exposure in the EU, Canada, China, and Taiwan? CFO Andrews says it’s “manageable” and already baked into guidance—a welcome relief for investors looking for steady margins.
Analyst sentiment was upbeat. Jason Wittes (ROTH) noted the “outsized growth” in specialized ortho, while Caitlin Cronin (Canaccord) pressed for the AccelStim 2.0 update—getting a confident launch timeline in return.
Bottom line: Orthofix is leaning into its dual spine-and-ortho identity with products that not only fill procedural gaps but also create cross-selling leverage. For an industry often defined by incrementalism, the company’s recent moves feel more like acceleration than just alignment.
